Compare Regeneron Pharmaceuticals Inc (REGN) vs Wolfspeed Inc (WOLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Wolfspeed Inc — how do they compare? Regeneron Pharmaceuticals Inc trades at $652.76 (market cap $70.79B), while Wolfspeed Inc trades at $29.23 (market cap $1.65B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 42.9× Wolfspeed Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.56% dividend while Wolfspeed Inc pays none. Which is the better fit depends on your goals.
| REGN | WOLF | |
|---|---|---|
Market Cap | $70.79B | $1.65B |
Sector | Health | Technology |
52-Week High | $812.27 | $73.68 |
52-Week Low | $545.46 | $1.19 |
Enterprise Value | $64.74B | $2.31B |
Dividend Yield | 0.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
Wolfspeed (WOLF) trades at $29.38, down 1.71% on the day, with a bearish technical outlook driven by moving averages but oversold RSI readings. The company shows negative profitability metrics, including a gross margin of -26.63% and net income margin of -79.83%, though it beat EPS estimates in two of the last three quarters. Recent news highlights strategic moves into data centers and defense, alongside a patent lawsuit against Navitas Semiconductor.
The outlook is mixed, with analyst consensus leaning neutral (47
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Wolfspeed Inc
Wolfspeed is the global leader in wide bandgap semiconductors, specializing in silicon carbide (SiC) and gallium nitride (GaN) materials and devices. It operates a vertically integrated model, controlling the entire process from raw material substrate production to advanced power modules, serving as a critical infrastructure provider for electric vehicles (EVs), renewable energy, and AI data centers.
Read more on WOLF →
